Sung H. Ferlay J. Siegel R.L. et al.

Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 71: 209-249Akateh C. Black S.M. Conteh L. et al.

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.

World J Gastroenterol. 25: 3704-3721Yopp A.C. Mansour J.C. Beg M.S. et al.

Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.

Ann Surg Oncol. 21: 1287-1295Mazzaferro V. Regalia E. Doci R. et al.

Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

N Engl J Med. 334: 693-699Pompili M. Mirante V.G. Rondinara G. et al.

Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence.

Liver Transpl. 11: 1117-1126Marubashi S. Gotoh K. Akita H. et al.

Anatomical versus non-anatomical resection for hepatocellular carcinoma.

Br J Surg. 102: 776-784Zhu H. Xing H. Yu B. et al.

Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China.

HPB (Oxford). 22: 1793-1802Li T. Qin L.X. Gong X. et al.

Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma.

Surgery. 156: 651-660Imamura H. Matsuyama Y. Tanaka E. et al.

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

J Hepatol. 38: 200-207Makuuchi M. Hasegawa H. Yamazaki S.

Ultrasonically guided subsegmentectomy.

Surg Gynecol Obstet. 161: 346-350Aoki T. Murakami M. Yasuda D. et al.

Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography.

J Hepatobiliary Pancreat Sci. 17: 590-594

A simplified method for controlled left hepatectomy.

Surgery. 97: 358-361

Glissonean pedicle transection method for hepatic resection: a new concept of liver segmentation.

J Hepato-Biliary-Pancreatic Surg. 5: 286-291

Anatomic vs. non-anatomic liver resection for hepatocellular carcinoma: standard of care or unfilled promises?.

Hepatoma Res. https://doi.org/10.20517/2394-5079.2021.66Zhou Y. Xu D. Wu L. et al.

Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.

Langenbecks Arch Surg. 396: 1109-1117Ye J.Z. Miao Z.G. Wu F.X. et al.

Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.

Asian Pac J Cancer Prev. 13: 1771-1777Cucchetti A. Cescon M. Ercolani G. et al.

A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.

Ann Surg Oncol. 19: 3697-3705Feng X. Su Y. Zheng S. et al.

A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence.

HPB (Oxford). 19: 667-674

A Meta-analysis comparing the effect of anatomical resection vs. non-anatomical resection on the long-term outcomes for patients undergoing hepatic resection for hepatocellular carcinoma.

HPB (Oxford). 19: 843-849Tan Y. Zhang W. Jiang L. et al.

Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: A systemic review and meta-analysis.

PLoS One. 12: e0186930Moris D. Tsilimigras D.I. Kostakis I.D. et al.

Anatomic versus non-anatomic resection for hepatocellular carcinoma: a systematic review and meta-analysis.

Eur J Surg Oncol. 44: 927-938Famularo S. Ceresoli M. Giani A. et al.

Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection.

J Gastrointest Surg. 25: 94-103Sun Z. Li Z. Shi X.L. et al.

Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.

Asian J Surg. 44: 1143-1150

Hepatic function and liver resection.

J Gastroenterol Hepatol. 5: 296-309Lai E.C.S. Fan S.-T.F. Lo C.-M. et al.

Anterior approach for difficult major right hepatectomy.

World J Surg. 20: 314-318Belghiti J. Guevara O.A. Noun R. et al.

Liver handing maneuver: a safe approach to right hepatectomy liver mobilization.

J Am Coll Surg. 193: 109-111Liu C.L. Fan S.T. Cheung S.T. et al.

Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study.

Ann Surg. 244: 194-203Beppu T. Imai K. Okuda K. et al.

Anterior approach for right hepatectomy with hanging maneuver for hepatocellular carcinoma: a multi-institutional propensity score-matching study.

J Hepatobiliary Pancreat Sci. 24: 127-136Chan K.M. Wang Y.C. Wu T.H. et al.

The preference for anterior approach major hepatectomy: experience over 3 decades and a propensity score-matching analysis in right hepatectomy for hepatocellular carcinoma.

Medicine (Baltimore). 94: e1385Otsubo T. Takasaki K. Yamamoto M. et al.

Bleeding during hepatectomy can be reduced by clamping the inferior vena cava below the liver.

Surgery. 135: 67-73Rahbari N.N. Koch M. Zimmermann J.B. et al.

Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial.

Ann Surg. 253: 1102-1110Zhou Y.M. Sui C.J. Zhang X.F. et al.

Anterior approach combined with infrahepatic inferior vena cava clamping right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled trial.

Medicine (Baltimore). 95: e4159Capussotti L. Ferrero A. Russolillo N. et al.

Routine anterior approach during right hepatectomy: results of a prospective randomised controlled trial.

J Gastrointest Surg. 16: 1324-1332Chen L.T. Chen M.F. Li L.A. et al.

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

Ann Surg. 255: 8-17Kubo S. Nishiguchi S. Hirohashi K. et al.

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.

Br J Surg. 89: 418-422Lo C.M. Liu C.L. Chan S.C. et al.

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Ann Surg. 245: 831-842Kubo S. Nishiguchi S. Hirohashi K. et al.

Effects of Long-Term Postoperative Interferon-Alpha Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma.

Ann Intern Med. 134: 963-967Ikeda K. Arase Y. Saitoh S. et al.

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.

Hepatology. 32: 228-232Huang G. Lau W.Y. Wang Z.G. et al.

Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.

Ann Surg. 261: 56-66Huang G. Li P.P. Lau W.Y. et al.

Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.

Ann Surg. 268: 943-954Yin J. LI N. Han Y. et al.

Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus– related hepatocellular carcinoma: a two-stage longitudinal clinical study.

J Clin Oncol. 31: 3647-3655Chen K. Xia Y. Wang H. et al.

Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial.

PLoS One. 8: e57397Llovet J.M. Ricci S. Mazzaferro V. et al.

Sorafenib in advanced hepatocellular carcinoma.

N Engl J Med. 359: 378-390Bruix J. Takayama T. Mazzaferro V. et al.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 16: 1344-1354Fujiwara H. Terashima M. Irinoda T. et al.

Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.

Jpn J Cancer Res. 93: 1342-1350Ishizuka M. Kubota K. Nemoto T. et al.

Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.

Asian J Surg. 39: 149-154

Capecitabine inhibition of recurrence and metastasis after liver cancer resection in nude mice.

Chin Med J. 39: 199-201Hoff P.M. Ansari R. Batist G. et al.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

J Clin Oncol. 19: 2282-2292Zhou J. Tang Z.-Y. Fan J. et al.

Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.

Clin Cancer Res. 9: 6030-6037Xia Y. Qiu Y. Li J. et al.

Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.

Ann Surg Oncol. 17: 3137-3144Finn R.S. Qin S. Ikeda M. et al.

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

N Engl J Med. 382: 1894-1905Finn R.S. Ryoo B.Y. Merle P. et al.

Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.

J Clin Oncol. 38: 193-202Zhu A.X. Finn R.S. Edeline J. et al.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Lancet Oncol. 19: 940-952Yau T. Kang Y.K. Kim T.Y. et al.

Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial.

JAMA Oncol. 6: e204564Yau T. Park J.-W. Finn R.S. et al.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Lancet Oncol. 23: 77-90El-Khoueiry A.B. Sangro B. Yau T. et al.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Lancet. 389: 2492-2502Kudo M. Ueshima K. Nakahira S. et al.

Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

J Clin Oncol. 40: 416Hack S.P. Spahn J. Chen M. et al.

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Future Oncol. 16: 975-989Jimenez Exposito M.J. Akce M. Montero Alvarez J.L. et al.

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.

Ann Oncol. 29: viii267-viii268https://doi.org/10.1093/annonc/mdy282.166Takayama T. Sekine T. Makuuchi M. et al.

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Lancet. 356: 802-807Hui D. Qiang L. Jian W. et al.

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.

Dig Liver Dis. 41: 36-41Lee J.H. Lee J.H. Lim Y.S. et al.

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

Gastroenterology. 148: 1383-13891 e6Yoo H.S.Y. Lee J.T. Kim K.W. et al.

Nodular hepatocellular carcinoma: treatment with subsegmental intraarterial injection of iodine z3 1-labeled iodized Oil.

Cancer. 68: 1878-1884Yumoto Y. Jinno K. Inatsuki S. et al.

Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution.

Cancer Chemother Pharmcol. 31: S128-S136Mantravadi R.V.P. Spigos D.C. Tan W.S. et al.

lntraarterial Yttrium 90 in the treatment of hepatic malignancy.

Radiology. 142: 783-786Partensky C. Sassolas G. Henry L. et al.

Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma.

Arch Surg. 135: 1298-1300Lau W.Y. Leung T.W.T. Ho S.K.W. et al.

Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.

The Lancet. 353: 797-801https://doi.org/10.1016/s0140-6736(98)06475-7Lau W.Y. Lai E.C. Leung T.W. et al.

Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.

Ann Surg. 247: 43-48Chung A.Y. Ooi L.L. Machin D. et al.

Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.

World J Surg. 37: 1356-1361Dumortier J. Decullier E. Hilleret M.N. et al.

Adjuvant Intraarterial Lipiodol or (1)(3)(1)I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.

J Nucl Med. 55: 877-883Zhong C. Guo R.P. Li J.Q. et al.

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma.

J Cancer Res Clin Oncol. 135: 1437-1445

TNM classification of malignant tumors.

6th edition. Wiley, Hoboken, NJWang Z. Ren Z. Chen Y. et al.

Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study.

Clin Cancer Res. 24: 2074-2081Hirokawa F. Komeda K. Taniguchi K. et al.

Is Postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial.

Ann Surg Oncol. 27: 4143-4152Li J. Xing J. Yang Y. et al.

Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial.

Lancet Gastroenterol Hepatol. 5: 548-560Li S. Mei J. Wang Q. et al.

Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial.

Ann Surg Oncol. 27: 5183-5190Yu W. Wang W. Rong W. et al.

Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm): a prospective randomized study.

J Am Coll Surg. 218: 381-392Sun J. Yang L. Shi J. et al.

Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial.

Radiother Oncol. 140: 20-25Zhou W.P. Lai E.C. Li A.J. et al.

A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Ann Surg. 249: 195-202Pinato D.J. Cortellini A. Sukumaran A. et al.

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

BMC Cancer. 21: 301Kaseb A.O. Pestana R.C. Vence L.M. et al.

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

J Clin Oncol. 37: 185Wei X. Jiang Y. Zhang X. et al.

Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.

J Clin Oncol. 37: 2141-2151